A new trading day began on Tuesday, with Cue Biopharma Inc (NASDAQ: CUE) stock price down -4.82% from the previous day of trading, before settling in for the closing price of $1.04. CUE’s price has ranged from $0.45 to $3.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 163.36% over the last five years. Meanwhile, its annual earnings per share averaged 33.69%. With a float of $62.87 million, this company’s outstanding shares have now reached $63.35 million.
The firm has a total of 53 workers. Let’s measure their productivity. In terms of profitability, gross margin is -17.81%, operating margin of -477.77%, and the pretax margin is -468.02%.
Cue Biopharma Inc (CUE) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cue Biopharma Inc is 0.75%, while institutional ownership is 23.54%. The most recent insider transaction that took place on Dec 16 ’24, was worth 30,900. In this transaction CHIEF EXECUTIVE OFFICER of this company bought 30,000 shares at a rate of $1.03, taking the stock ownership to the 164,578 shares.
Cue Biopharma Inc (CUE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.69% per share during the next fiscal year.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
Here are Cue Biopharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Cue Biopharma Inc (CUE)
Analysing the last 5-days average volume posted by the [Cue Biopharma Inc, CUE], we can find that recorded value of 0.34 million was lower than the volume posted last year of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 33.01%. Additionally, its Average True Range was 0.14.
During the past 100 days, Cue Biopharma Inc’s (CUE) raw stochastic average was set at 36.38%, which indicates a significant increase from 29.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.84% in the past 14 days, which was lower than the 146.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2980, while its 200-day Moving Average is $1.2554. Now, the first resistance to watch is $1.0500. This is followed by the second major resistance level at $1.0900. The third major resistance level sits at $1.1250. If the price goes on to break the first support level at $0.9750, it is likely to go to the next support level at $0.9400. Now, if the price goes above the second support level, the third support stands at $0.9000.
Cue Biopharma Inc (NASDAQ: CUE) Key Stats
With a market capitalization of 62.71 million, the company has a total of 63,350K Shares Outstanding. Currently, annual sales are 5,490 K while annual income is -50,730 K. The company’s previous quarter sales were 3,340 K while its latest quarter income was -8,660 K.
